Budd-Chiari syndrome in Behçet's disease : a retrospective multicenter study
© 2021. International League of Associations for Rheumatology (ILAR)..
OBJECTIVE: To compare the clinical features, laboratory findings, and prognosis of Behçet's disease (BD) patients with and without Budd-Chiari syndrome (BCS).
METHODS: This multicenter retrospective study investigated 61 (M/F: 41/20) patients with BD, having coexistent BCS, and 169 (M/F:100/69) BD patients as the control group without BCS from 22 different centers of Turkey diagnosed between 1990 and 2017.
RESULTS: Of the total 61 BD patients with BCS, the onset of the first symptom and the median age of diagnosis were earlier in contrast to BD patients without BCS (p = 0.005 and p = 0.007). Lower extremity deep vein and inferior vena cava (IVC) thrombosis were more common in patients with BCS (all; p < 0.01) compared to the control group. Mortality was significantly higher in BD-BCS patients with IVC thrombosis than in the controls (p = 0.004). Since most of the cases in our cohort had chronic and silent form of BCS, mortality rate was 14.8%, which was on the lower range of mortality rate reported in literature (14-47%). While all BD-BCS patients received immunosuppressive (IS) agents, only half of them received additional anticoagulant treatments. Among IS agents, interferon treatment was more frequently used in this cohort (19%), compared to other series reported in literature (2.3%).
CONCLUSION: To our knowledge, this is the largest series of BD patients with BCS. Our patients had earlier disease onset and diagnosis, higher frequency of IVC thrombosis, and higher mortality rate, compared to BD patients without BCS. Mortality was significantly higher in BD-BCS patients with IVC thrombosis compared to controls. Key Points • Mortality rate is higher in BD-associated BCS patients with IVC involvement. • Chronic and silent form of BD-associated BCS has a better prognosis. • The main treatment options are corticosteroids and immunosuppressive agents, whereas anticoagulant treatment remains controversial.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Clinical rheumatology - 41(2022), 1 vom: 09. Jan., Seite 177-186 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Akyol, Lütfi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Behçet’s disease |
|---|
| Anmerkungen: |
Date Completed 05.01.2022 Date Revised 05.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10067-021-05878-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32913079X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32913079X | ||
| 003 | DE-627 | ||
| 005 | 20231225204438.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10067-021-05878-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1097.xml |
| 035 | |a (DE-627)NLM32913079X | ||
| 035 | |a (NLM)34368908 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Akyol, Lütfi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Budd-Chiari syndrome in Behçet's disease |b a retrospective multicenter study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.01.2022 | ||
| 500 | |a Date Revised 05.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. International League of Associations for Rheumatology (ILAR). | ||
| 520 | |a OBJECTIVE: To compare the clinical features, laboratory findings, and prognosis of Behçet's disease (BD) patients with and without Budd-Chiari syndrome (BCS) | ||
| 520 | |a METHODS: This multicenter retrospective study investigated 61 (M/F: 41/20) patients with BD, having coexistent BCS, and 169 (M/F:100/69) BD patients as the control group without BCS from 22 different centers of Turkey diagnosed between 1990 and 2017 | ||
| 520 | |a RESULTS: Of the total 61 BD patients with BCS, the onset of the first symptom and the median age of diagnosis were earlier in contrast to BD patients without BCS (p = 0.005 and p = 0.007). Lower extremity deep vein and inferior vena cava (IVC) thrombosis were more common in patients with BCS (all; p < 0.01) compared to the control group. Mortality was significantly higher in BD-BCS patients with IVC thrombosis than in the controls (p = 0.004). Since most of the cases in our cohort had chronic and silent form of BCS, mortality rate was 14.8%, which was on the lower range of mortality rate reported in literature (14-47%). While all BD-BCS patients received immunosuppressive (IS) agents, only half of them received additional anticoagulant treatments. Among IS agents, interferon treatment was more frequently used in this cohort (19%), compared to other series reported in literature (2.3%) | ||
| 520 | |a CONCLUSION: To our knowledge, this is the largest series of BD patients with BCS. Our patients had earlier disease onset and diagnosis, higher frequency of IVC thrombosis, and higher mortality rate, compared to BD patients without BCS. Mortality was significantly higher in BD-BCS patients with IVC thrombosis compared to controls. Key Points • Mortality rate is higher in BD-associated BCS patients with IVC involvement. • Chronic and silent form of BD-associated BCS has a better prognosis. • The main treatment options are corticosteroids and immunosuppressive agents, whereas anticoagulant treatment remains controversial | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Behçet’s disease | |
| 650 | 4 | |a Budd–Chiari syndrome | |
| 650 | 4 | |a Inferior vena cava | |
| 650 | 4 | |a Prognosis | |
| 650 | 4 | |a Thrombosis | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 700 | 1 | |a Toz, Bahtiyar |e verfasserin |4 aut | |
| 700 | 1 | |a Bayındır, Özün |e verfasserin |4 aut | |
| 700 | 1 | |a Zengin, Orhan |e verfasserin |4 aut | |
| 700 | 1 | |a Cansu, DöndüÜsküdar |e verfasserin |4 aut | |
| 700 | 1 | |a Yiğit, Murat |e verfasserin |4 aut | |
| 700 | 1 | |a Çetin, Gözde Yıldırım |e verfasserin |4 aut | |
| 700 | 1 | |a Omma, Ahmet |e verfasserin |4 aut | |
| 700 | 1 | |a Erden, Abdulsamet |e verfasserin |4 aut | |
| 700 | 1 | |a Küçükşahin, Orhan |e verfasserin |4 aut | |
| 700 | 1 | |a Altuner, Mehmet Şakir |e verfasserin |4 aut | |
| 700 | 1 | |a Çorba, BurçinŞeyda |e verfasserin |4 aut | |
| 700 | 1 | |a Ünal, Ali Uğur |e verfasserin |4 aut | |
| 700 | 1 | |a Küçük, Hamit |e verfasserin |4 aut | |
| 700 | 1 | |a Küçük, Adem |e verfasserin |4 aut | |
| 700 | 1 | |a Balkarli, Ayşe |e verfasserin |4 aut | |
| 700 | 1 | |a Gönüllü, Emel |e verfasserin |4 aut | |
| 700 | 1 | |a Tufan, Ayşe Nur |e verfasserin |4 aut | |
| 700 | 1 | |a Bakırcı, Sibel |e verfasserin |4 aut | |
| 700 | 1 | |a Öner, Sibel Yılmaz |e verfasserin |4 aut | |
| 700 | 1 | |a Balcı, Mehmet Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Kobak, Şenol |e verfasserin |4 aut | |
| 700 | 1 | |a Yazıcı, Ayten |e verfasserin |4 aut | |
| 700 | 1 | |a Özgen, Metin |e verfasserin |4 aut | |
| 700 | 1 | |a Şahin, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Koca, Süleyman Serdar |e verfasserin |4 aut | |
| 700 | 1 | |a Erer, Burak |e verfasserin |4 aut | |
| 700 | 1 | |a Gül, Ahmet |e verfasserin |4 aut | |
| 700 | 1 | |a Aksu, Kenan |e verfasserin |4 aut | |
| 700 | 1 | |a Keser, Gökhan |e verfasserin |4 aut | |
| 700 | 1 | |a Onat, Ahmet Mesut |e verfasserin |4 aut | |
| 700 | 1 | |a Kısacık, Bünyamin |e verfasserin |4 aut | |
| 700 | 1 | |a Kaşifoğlu, Timuçin |e verfasserin |4 aut | |
| 700 | 1 | |a Çefle, Ayşe |e verfasserin |4 aut | |
| 700 | 1 | |a Kalyoncu, Umut |e verfasserin |4 aut | |
| 700 | 1 | |a Sayarlıoğlu, Mehmet |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical rheumatology |d 1987 |g 41(2022), 1 vom: 09. Jan., Seite 177-186 |w (DE-627)NLM012613037 |x 1434-9949 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2022 |g number:1 |g day:09 |g month:01 |g pages:177-186 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10067-021-05878-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2022 |e 1 |b 09 |c 01 |h 177-186 | ||